

Cardiovascular Drug Delivery

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" published by Humana/Springer (1st ed 2008; 2nd ed 2014). His other recent relevant books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition, Peking University Press 2011, 3rd ed Springer 2017) and "Textbook of Personalized Medicine", (Springer 2009; Japanese edition 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), and "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011).

A B O U T T H I S R E P O R T

The original report on Cardiovascular Drug Delivery appeared as a chapter in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery. Cardiovascular Drug Delivery has now been detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech.

November 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

| | |
|---|-----------|
| 0. Executive Summary | 10 |
| 1. Cardiovascular Diseases | 12 |
| Introduction..... | 12 |
| History of cardiovascular drug delivery..... | 12 |
| Overview of cardiovascular disease | 13 |
| Coronary artery disease..... | 13 |
| <i>Angina pectoris.....</i> | <i>13</i> |
| <i>Myocardial infarction</i> | <i>13</i> |
| <i>Limitations of current therapies for myocardial ischemic disease</i> | <i>14</i> |
| Cardiomyopathies | 14 |
| Cardiac arrhythmias | 14 |
| Congestive heart failure..... | 15 |
| Peripheral arterial disease | 15 |
| <i>Current management</i> | <i>16</i> |
| Atherosclerosis | 16 |
| The endothelium as a target for cardiovascular therapeutics..... | 16 |
| Molecular cardiology | 16 |
| Cardiogenomics | 16 |
| Cardioproteomics | 17 |
| Personalized cardiology | 17 |
| Pharmacogenomics of cardiovascular disorders | 18 |
| Modifying the genetic risk for myocardial infarction | 18 |
| Management of heart failure..... | 19 |
| Management of hypertension..... | 19 |
| <i>Pharmacogenomics of diuretic drugs.....</i> | <i>20</i> |
| <i>Pharmacogenomics of ACE inhibitors</i> | <i>20</i> |
| <i>Management of hypertension by personalized approach</i> | <i>20</i> |
| Pharmacogenetics of lipid-lowering therapies..... | 20 |
| <i>Polymorphisms in genes involved in cholesterol metabolism</i> | <i>21</i> |
| <i>Role of eNOS gene polymorphisms</i> | <i>21</i> |
| Important advances in cardiovascular therapeutics..... | 22 |
| Drug delivery, biotechnology and the cardiovascular system..... | 22 |
| Role of cardiovascular imaging in cardiovascular therapeutics | 23 |
| Biologic therapeutics for cardiovascular disorders..... | 23 |
| Chronopharmacotherapy of cardiovascular diseases | 23 |
| 2. Methods for Drug Delivery to the Cardiovascular System | 26 |
| Introduction..... | 26 |
| Routes of drug delivery to the cardiovascular system..... | 26 |
| Local administration of drugs to the cardiovascular system | 26 |
| Intramyocardial drug delivery..... | 26 |
| Drug delivery via coronary venous system | 27 |
| Intrapericardial drug delivery | 27 |
| Formulations for drug delivery to the cardiovascular system..... | 28 |
| Sustained and controlled release..... | 28 |
| <i>Programming the release at a defined time</i> | <i>29</i> |
| <i>Dosage formulation of calcium channel blockers.....</i> | <i>29</i> |
| <i>Sustained and controlled release verapamil.....</i> | <i>29</i> |
| Methods of administration of proteins and peptides | 29 |
| <i>Delivery of peptides by subcutaneous injection</i> | <i>30</i> |
| <i>Depot formulations and implants.....</i> | <i>30</i> |
| <i>Poly(ethylene glycol) technology</i> | <i>30</i> |
| <i>Liposomes for cardiovascular drug delivery</i> | <i>31</i> |
| <i>Microencapsulation for protein delivery</i> | <i>31</i> |
| <i>Localized delivery of biomaterials for tissue engineering.....</i> | <i>31</i> |
| <i>Oral delivery of proteins and peptides.....</i> | <i>31</i> |
| Monoclonal antibodies for cardiovascular disorders..... | 33 |
| Abciximab | 34 |
| Canakinumab | 34 |
| PCSK9 MAbs..... | 34 |
| DDS to improve systemic delivery of cardiovascular drugs | 34 |
| Nanotechnology-based drug delivery..... | 35 |
| Controlled delivery of nanoparticles to injured vasculature | 36 |
| Nanoparticles for cardiovascular imaging and targeted drug delivery | 36 |
| Nanofiber-based scaffolds with drug-release properties..... | 37 |
| Targeted drug delivery to the cardiovascular system..... | 37 |

| | |
|--|-----------|
| Immunotargeting of liposomes to activated vascular endothelial cells | 38 |
| PEGylated biodegradable particles targeted to inflamed endothelium | 38 |
| Drug delivery in the management of cardiovascular disease | 39 |
| Local drug delivery by catheters | 39 |
| Microneedle for periarterial injection | 41 |
| Nanotechnology-based devices for the cardiovascular system | 42 |
| <i>Liposomal nanodevices for targeted cardiovascular drug delivery</i> | 42 |
| <i>Nanotechnology approach to the problem of "vulnerable plaque"</i> | 42 |
| Drug delivery in the management of cardiovascular disease | 43 |
| Drug delivery in the management of hypertension | 43 |
| <i>Transnasal drug delivery for hypertension</i> | 44 |
| <i>Transdermal drug delivery for hypertension</i> | 44 |
| <i>Oral extended and controlled release preparations for hypertension</i> | 44 |
| <i>Long-acting hypertensives for 24 h blood pressure control</i> | 45 |
| <i>Drug delivery to control early morning blood pressure peak</i> | 45 |
| <i>Role of drug delivery in improving compliance with antihypertensive therapy</i> | 46 |
| <i>Vaccines for hypertension</i> | 46 |
| Drug delivery in the treatment of angina pectoris | 47 |
| <i>Sustained and controlled-release nitrate for angina pectoris</i> | 47 |
| <i>Transdermal nitrate therapy</i> | 47 |
| <i>Controlled release calcium blockers for angina pectoris</i> | 48 |
| <i>Sustained-release formulation of ranolazine</i> | 49 |
| DDS in the management of ischemic heart disease | 49 |
| <i>Intravenous emulsified formulations of halogenated anesthetics</i> | 50 |
| <i>Injectable peptide nanofibers for myocardial ischemia</i> | 50 |
| <i>Delivery of angiogenesis-inducing agents for myocardial ischemia</i> | 50 |
| Drug delivery for myocardial infarction | 51 |
| Drug delivery for cardioprotection | 52 |
| <i>Cardioprotection during reperfusion</i> | 54 |
| Drug delivery for congestive heart failure | 55 |
| <i>Oral human brain-type natriuretic peptide</i> | 55 |
| <i>Nitric oxide-based therapies for congestive heart failure</i> | 55 |
| <i>Automated drug delivery system for cardiac failure</i> | 55 |
| Drug delivery for cardiac rhythm disorders | 56 |
| Drug delivery in the management of pulmonary hypertension | 56 |
| <i>Endothelin receptor antagonist treatment of PAH</i> | 57 |
| <i>Prostacyclin by inhalation</i> | 57 |
| <i>Treprostinil</i> | 57 |
| Anticoagulation in cardiovascular disease | 57 |
| <i>Oral heparin</i> | 58 |
| <i>Low molecular weight heparin-loaded polymeric nanoparticles</i> | 58 |
| <i>Transdermal anticoagulants</i> | 58 |
| Thrombolysis for cardiovascular disorders | 59 |
| <i>Use of ultrasound to facilitate thrombolysis</i> | 59 |
| <i>Delivery of alteplase through the AngioJet rheolytic catheter</i> | 59 |
| Drug delivery for peripheral arterial disease | 59 |
| <i>Delivery of thrombolytic agent to the clot through a catheter</i> | 60 |
| <i>Delivery of growth factors to promote angiogenesis in ischemic limbs</i> | 60 |
| <i>Immune modulation therapy for PAD</i> | 60 |
| <i>NO-based therapies for peripheral arterial disease</i> | 61 |
| Drug delivery in the management of hypercholesterolemia | 61 |
| <i>Controlled/sustained release formulations of statins</i> | 61 |
| <i>Combinations of statins with other drugs to increase efficacy</i> | 62 |
| <i>Controlled release fenofibrate</i> | 63 |
| <i>Extended release nicotinic acid</i> | 63 |
| <i>Intravenous infusion of lipoprotein preparations to raise HDL</i> | 64 |
| <i>Innovative approaches to hypercholesterolemia</i> | 65 |
| <i>Therapeutic antagonism of ANGPTL3 gene</i> | 65 |
| <i>Vaccines for lowering cholesterol by targeting PCSK9</i> | 67 |
| Single dose therapy for more than one cardiovascular disorder | 67 |
| 3. Cell Therapy for Cardiovascular Disorders | 68 |
| Introduction | 68 |
| Inducing the proliferation of cardiomyocytes | 68 |
| Role of stem cells in repair of the heart | 68 |
| Cell-mediated immune modulation for chronic heart disease | 68 |
| Cell therapy for atherosclerotic coronary artery disease | 69 |
| Transplantation of myoblasts for myocardial infarction | 69 |
| <i>MyoCell™ (Bioheart)</i> | 70 |
| Transplantation of cardiac progenitor cells for revascularization of myocardium | 71 |
| Methods of delivery of cells to the heart | 71 |

| | |
|---|-----------|
| Cellular cardiomyoplasty | 71 |
| IGF-1 delivery by nanofibers to improve cell therapy for MI..... | 72 |
| Intracoronary infusion of bone marrow-derived cells for AMI | 72 |
| Non-invasive delivery of cells to the heart by Morph@guide catheter | 72 |
| Transplantation of stem cells for myocardial infarction | 73 |
| <i>Transplantation of embryonic stem cells</i> | 73 |
| <i>Transplantation of hematopoietic stem cells</i> | 73 |
| <i>Transplantation of cord blood stem cells for myocardial infarction</i> | 73 |
| <i>Intracoronary infusion of mobilized peripheral blood stem cells</i> | 74 |
| <i>Human mesenchymal stem cells for cardiac regeneration</i> | 74 |
| <i>Cytokine preconditioning of human fetal liver CD133+ SCs</i> | 75 |
| <i>Transplantation of expanded adult SCs derived from the heart</i> | 75 |
| <i>Transplantation of endothelial cells</i> | 75 |
| Transplantation of genetically modified cells | 76 |
| <i>Transplantation of cells secreting vascular endothelial growth factor</i> | 76 |
| <i>Transplantation of genetically modified bone marrow stem cells</i> | 76 |
| Cell transplantation for congestive heart failure | 76 |
| <i>Injection of adult stem cells for congestive heart failure</i> | 76 |
| <i>Intracoronary infusion of cardiac stem cells</i> | 77 |
| <i>Myoblasts for treatment of congestive heart failure</i> | 77 |
| Role of cell therapy in cardiac arrhythmias | 77 |
| <i>Atrioventricular conduction block</i> | 78 |
| <i>Ventricular tachycardia</i> | 78 |
| <i>ESCs for correction of congenital heart defects</i> | 79 |
| Cardiac progenitors cells for treatment of heart disease in children | 79 |
| Stem cell therapy for peripheral arterial disease | 80 |
| Targeted delivery of endothelial progenitor cells labeled with nanoparticles | 80 |
| Clinical trials of cell therapy in cardiovascular disease | 80 |
| A critical evaluation of cell therapy for heart disease | 83 |
| Publications of clinical trials of cell therapy for CVD | 83 |
| Future directions for cell therapy of CVD | 83 |
| Prospects of adult stem cell therapy for repair of heart | 84 |
| Regeneration of cardiomyocytes without use of cardiac stem cells | 85 |
| Repair of the damaged heart | 85 |
| | |
| 4. Gene Therapy for Cardiovascular Disorders | 88 |
| Introduction..... | 88 |
| Techniques of gene transfer to the cardiovascular system..... | 89 |
| Direct plasmid injection into the myocardium | 89 |
| Catheter-based systems for vector delivery | 89 |
| Ultrasound microbubbles for cardiovascular gene delivery | 90 |
| Vectors for cardiovascular gene therapy..... | 90 |
| <i>AAV vectors for therapeutic delivery to the heart</i> | 90 |
| <i>Adenoviral vectors for cardiovascular diseases</i> | 91 |
| <i>Plasmid DNA-based delivery in cardiovascular disorders</i> | 91 |
| Hypoxia-regulated gene therapy for myocardial ischemia | 91 |
| Angiogenesis and gene therapy of ischemic disorders | 92 |
| Therapeutic angiogenesis vs. vascular growth factor therapy | 93 |
| Gene painting for delivery of targeted gene therapy to the heart..... | 93 |
| Gene delivery to vascular endothelium | 93 |
| <i>Overexpression of eNOS to improve vasodilation with Ad vectors</i> | 93 |
| Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles | 94 |
| Gene therapy for genetic cardiovascular disorders | 94 |
| Genetic disorders predisposing to atherosclerosis..... | 94 |
| Familial hypercholesterolemia..... | 95 |
| Apolipoprotein E deficiency..... | 96 |
| Hypertension | 96 |
| Genetic factors for myocardial infarction | 97 |
| Acquired cardiovascular diseases | 97 |
| Coronary artery disease with angina pectoris..... | 97 |
| <i>Ad5FGF-4</i> | 97 |
| Ischemic heart disease with myocardial infarction | 98 |
| <i>Angiogenesis for cardiovascular disease</i> | 99 |
| <i>Myocardial repair with IGF-1 therapy</i> | 99 |
| <i>miRNA gene therapy for ischemic heart disease</i> | 100 |
| Congestive heart failure | 100 |
| <i>Rationale of gene therapy in CHF</i> | 100 |
| <i>AAV-mediated gene transfer for CHF</i> | 101 |
| <i>AngioCell gene therapy for CHF</i> | 101 |
| <i>β-ARKct gene therapy</i> | 101 |
| <i>Elevating cardiac dATP by gene therapy to improve cardiac function</i> | 102 |

| | |
|---|------------|
| <i>Intracoronary adenovirus-mediated gene therapy for CHF</i> | 103 |
| <i>nNOS gene transfer in CHF</i> | 103 |
| Gene therapy for cardiac arrhythmias..... | 103 |
| <i>Gene transfer for biological pacemakers</i> | 104 |
| <i>Management of arrhythmias due to myoblast transplantation</i> | 104 |
| <i>Genetically engineered cells as biological pacemakers</i> | 105 |
| Cholesterol reduction by genetic engineering of PCSK9 gene..... | 105 |
| Gene therapy and heart transplantation..... | 106 |
| Gene therapy for peripheral arterial disease..... | 106 |
| <i>Angiogenesis by gene therapy</i> | 106 |
| <i>HIF-1α gene therapy for peripheral arterial disease</i> | 106 |
| <i>HGF gene therapy for peripheral arterial disease</i> | 107 |
| <i>Ischemic neuropathy secondary to peripheral arterial disease</i> | 107 |
| Maintaining vascular patency after surgery..... | 108 |
| Antisense therapy for cardiovascular disorders..... | 108 |
| Antisense therapy for hypertension..... | 109 |
| Antisense therapy for hypercholesterolemia..... | 109 |
| <i>Mipomersen</i> | 109 |
| <i>Antisense oligonucleotides targeting ANGPTL3</i> | 110 |
| <i>Antisense drugs targeting PCSK9</i> | 110 |
| RNAi for cardiovascular disorders..... | 110 |
| RNAi for hypercholesterolemia..... | 111 |
| <i>siRNAs targeting PCSK9</i> | 111 |
| microRNA and the cardiovascular system..... | 111 |
| <i>Role of miRNAs in angiogenesis</i> | 112 |
| <i>Role of miRNAs in cardiac hypertrophy and failure</i> | 112 |
| <i>Role of miRNAs in conduction and rhythm disorders of the heart</i> | 113 |
| <i>miRNA-based approach for reduction of hypercholesterolemia</i> | 113 |
| <i>miRNAs as therapeutic targets for cardiovascular diseases</i> | 113 |
| <i>Future prospects of miRNA in the cardiovascular therapeutics</i> | 114 |
| Future prospects of gene therapy of cardiovascular disorders..... | 114 |
| Companies involved in gene therapy of cardiovascular disorders..... | 115 |
| 5. Drug-Eluting Stents..... | 116 |
| Introduction..... | 116 |
| Percutaneous transluminal coronary angioplasty..... | 116 |
| Stents..... | 116 |
| Restenosis..... | 116 |
| Pathomechanism..... | 117 |
| Treatment..... | 117 |
| Nitric oxide-based therapies for restenosis..... | 118 |
| Carbon monoxide inhalation for preventing restenosis..... | 118 |
| Antisense approaches for prevention of restenosis after angioplasty..... | 119 |
| Gene therapy to prevent restenosis after angioplasty..... | 119 |
| <i>Delivery of gene therapy for restenosis</i> | 119 |
| <i>HSV-1 gene therapy to prevent intimal hyperplasia</i> | 119 |
| <i>miRNA-based gene therapy for restenosis following angioplasty</i> | 120 |
| <i>Nonviral gene therapy to prevent intimal hyperplasia</i> | 120 |
| <i>NOS gene therapy for restenosis</i> | 120 |
| <i>Targets for gene therapy of restenosis</i> | 121 |
| <i>Viral vector-mediated gene therapy for restenosis</i> | 122 |
| Drug delivery devices for restenosis..... | 123 |
| Local drug delivery by catheter..... | 123 |
| Stenosis associated with stents..... | 124 |
| Absorbable metal stents..... | 124 |
| Drug-eluting stents..... | 124 |
| Various types of DES..... | 125 |
| <i>CYPHER$\text{\textcircled{R}}$ sirolimus-eluting coronary stent</i> | 125 |
| <i>Dexamethasone-eluting stents</i> | 125 |
| <i>NO-generating stents</i> | 126 |
| <i>Paclitaxel-eluting stents</i> | 126 |
| <i>Sirolimus-eluting vs paclitaxel-eluting stents</i> | 127 |
| Novel technologies for DES..... | 127 |
| <i>Bio-absorbable DES</i> | 127 |
| <i>Drug-eluting stents coated with polymer surfaces</i> | 128 |
| <i>Endeavour DES</i> | 128 |
| <i>Polymer-free drug-coated stent for patients at high risk of bleeding</i> | 129 |
| <i>Stents for delivery of gene therapy</i> | 130 |
| <i>Stem cell-based stents</i> | 130 |
| <i>VAN 10-4 DES</i> | 131 |
| Nanotechnology-based stents..... | 131 |

| | |
|---|------------|
| <i>Drugs encapsulated in biodegradable nanoparticles</i> | 131 |
| <i>Magnetic nanoparticle-coated DES</i> | 131 |
| <i>Magnetic nanoparticles encapsulating paclitaxel targeted to stents</i> | 133 |
| <i>Nanocoated DES</i> | 133 |
| <i>Nanopores to enhance compatibility of DES</i> | 134 |
| <i>Paclitaxel-encapsulated targeted lipid-polymeric nanoparticles</i> | 134 |
| The ideal DES | 134 |
| Companies developing drug-eluting stents | 135 |
| Clinical trials of drug-eluting stents | 136 |
| <i>Measurements used in clinical trials of DES</i> | 136 |
| <i>TAXUS paclitaxel-eluting stents</i> | 136 |
| <i>XIENCE™ V everolimus-eluting coronary stent</i> | 137 |
| <i>COSTAR II clinical trial</i> | 138 |
| <i>Endeavor RESOLUTE zotarolimus-eluting stent system</i> | 138 |
| <i>CUSTOM I clinical trial</i> | 139 |
| <i>NOBORI CORE Trial</i> | 139 |
| <i>LEADERS trial</i> | 140 |
| <i>Comparison of DES releasing either zotarolimus or everolimus</i> | 140 |
| Comparison of DES versus bare metal stents in clinical trials | 140 |
| <i>Biosorbable vs drug-eluting metallic stents</i> | 143 |
| <i>Multi-Link Vision bare metal stent vs DES</i> | 144 |
| <i>Guidelines for DES vs BMS</i> | 144 |
| <i>DES vs BMS for off-label indications</i> | 144 |
| <i>Role of DES in cases of bare-metal in-stent restenosis</i> | 145 |
| Comparison of revascularization methods for stable coronary disease | 145 |
| <i>DES versus coronary artery bypass graft</i> | 145 |
| <i>DES versus balloon catheter coated with paclitaxel</i> | 146 |
| <i>DES versus intracoronary radiation therapy for recurrent stenosis</i> | 146 |
| <i>PCI plus DES as the preferred method for treatment of MI</i> | 147 |
| Cost-effectiveness of DES | 147 |
| Safety issues of DES | 148 |
| <i>Adverse reactions to DES</i> | 148 |
| <i>Long-term safety studies of DES</i> | 149 |
| <i>Endothelial vascular dysfunction due to sirolimus</i> | 150 |
| <i>Risk of clotting with DES</i> | 150 |
| <i>Effect of blood clot on release of drug from DES</i> | 151 |
| Measures to prevent clotting associated with DES | 152 |
| <i>Clopidogrel use and long-term outcomes of patients receiving DES</i> | 152 |
| <i>Cangrelor for platelet inhibition to prevent stent thrombosis</i> | 152 |
| <i>Prasugrel as antiplatelet agent</i> | 152 |
| <i>Use of magnetized cell lining to prevent clotting of DES</i> | 153 |
| Regulatory issues of DES | 153 |
| Approved drug-eluting stents | 153 |
| Safety issues of drug-eluting stents | 154 |
| Assessment of efficacy of various drug-eluting stents | 155 |
| Future prospects of treatment of restenosis by DES | 155 |
| Effect of stent cost on clinical applications | 155 |
| Future role of DES in the management of cardiovascular diseases | 156 |
| Improvements in stent technology | 156 |
| <i>Bioabsorbable stent</i> | 157 |
| DES vs drug-eluting balloons | 157 |
| 6. Markets for Cardiovascular Drug Delivery | 158 |
| Introduction | 158 |
| Epidemiology of cardiovascular disease | 158 |
| Cost of care of cardiovascular disorders | 159 |
| Cardiovascular markets according to important diseases | 160 |
| Antithrombotics | 160 |
| Anticholesterol agents | 160 |
| Antihypertensive agents | 161 |
| Drugs for congestive heart failure | 161 |
| Markets for innovative technologies for cardiovascular disorders | 161 |
| Markets for cell therapy of cardiovascular disorders | 161 |
| Markets for gene therapy of cardiovascular disorders | 162 |
| Markets for drug-eluting stents | 162 |
| <i>Major players in DES market</i> | 162 |
| <i>Impact of safety issues on future markets for DES</i> | 162 |
| <i>DES market in Asia</i> | 163 |
| <i>Patenting and legal issues of DES</i> | 164 |
| <i>The financial impact of DES on cardiovascular markets</i> | 164 |
| Unmet needs for cardiovascular drug delivery | 165 |

| | |
|---|------------|
| Role of DDS in developing cardiovascular markets | 165 |
| Markets for cardiovascular devices | 166 |
| Marketing of innovative cardiovascular drug delivery devices..... | 166 |
| Direct to consumer advertising of DES | 166 |
| Future trends in the integration of drug delivery with therapeutics | 167 |
| Future of cardiovascular drug delivery | 167 |
| 7. Companies involved in Cardiovascular Drug Delivery | 168 |
| Profiles of companies..... | 168 |
| Collaborations..... | 256 |
| 8. References..... | 260 |

Tables

| | |
|--|-----|
| Table 1-1: Landmarks in the historical evolution of cardiovascular drug delivery | 12 |
| Table 1-2: Approaches to management of myocardial infarction and its sequele | 13 |
| Table 1-3: Gene polymorphisms that alter cardiovascular response to drugs | 18 |
| Table 2-1: Routes of drug delivery used for treatment of cardiovascular disorders | 26 |
| Table 2-2: Formulations for drug delivery to the cardiovascular system | 28 |
| Table 2-3: Monoclonal antibodies used for cardiovascular disorders..... | 33 |
| Table 2-4: Improved methods of systemic drug delivery of cardiovascular drugs | 35 |
| Table 2-5: Targeted delivery of therapeutic substances to the cardiovascular system | 38 |
| Table 2-6: Classification of devices for drug delivery to the cardiovascular system | 39 |
| Table 2-7: Various methods of delivery of therapeutic agents for hypertension..... | 43 |
| Table 2-8: Marketed controlled/ extended release preparation for hypertension..... | 45 |
| Table 2-9: Methods of delivery of nitrate therapy in angina pectoris | 47 |
| Table 2-10: Drug delivery in ischemic heart disease | 49 |
| Table 2-11: Strategies for cardioprotection | 52 |
| Table 2-12: Drug delivery for peripheral arterial disorders | 60 |
| Table 3-1: Clinical trials of cell therapy in cardiovascular disease | 80 |
| Table 4-1: Cardiovascular disorders for which gene therapy is being considered. | 88 |
| Table 4-2: Catheter-based systems for vector delivery to the cardiovascular system | 89 |
| Table 4-3: Potential applications of antisense in cardiovascular disorders | 109 |
| Table 4-4: Companies involved in gene therapy of cardiovascular diseases | 115 |
| Table 5-1: Treatment of restenosis | 117 |
| Table 5-2: Devices used for drug delivery in restenosis | 123 |
| Table 5-3: Companies involved in drug-eluting stents..... | 135 |
| Table 5-4: Drug-eluting stents approved by the FDA | 153 |
| Table 6-1: Prevalence of cardiovascular disorders in major markets: US 2016-2026 | 159 |
| Table 6-2: Prevalence of cardiovascular disorders in major markets: Europe 2016-2026..... | 159 |
| Table 6-3: Prevalence of cardiovascular disorders in major markets: Japan 2016-2026 | 159 |
| Table 6-4: Values of cardiovascular DDS in major markets 2016-2026 | 160 |
| Table 6-5: Markets for innovative technologies for cardiovascular disorders 2016-2026..... | 161 |
| Table 7-1: Top 5 companies in cardiovascular drug delivery | 168 |
| Table 7-2: Collaborations in cardiovascular drug delivery | 256 |

Figures

| | |
|--|-----|
| Figure 1-1: Drug delivery, biotechnology and cardiovascular diseases | 22 |
| Figure 2-1: MicroSyringe for periarterial injection | 41 |
| Figure 2-2: Patch for delivery of follistatin-like 1 factor for myocardial infarction..... | 52 |
| Figure 2-3: Lipoprotein metabolism in ANGPTL3 deficiency..... | 66 |
| Figure 5-1: Vicious circle of vascular occlusion following angioplasty and stenting | 118 |
| Figure 5-2: Measurement of in-stent stenosis..... | 124 |
| Figure 5-3: Medtronic's Endeavour drug-eluting stent..... | 129 |
| Figure 5-4: Magnetic nanoparticle-coated stent | 133 |
| Figure 6-1: Unmet needs for cardiovascular drug delivery | 165 |